Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences
13. Mai 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
06. Mai 2021 07:30 ET
|
Protara Therapeutics
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with...
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
23. April 2021 07:00 ET
|
Protara Therapeutics
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19. April 2021 16:09 ET
|
Protara Therapeutics
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
19. April 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
11. März 2021 07:30 ET
|
Protara Therapeutics
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for...
Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference
10. März 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
04. Februar 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. Februar 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
02. Februar 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...